Approval · Notice of Compliance 30657 · 2023
ERAXIS: Notice of Compliance 30657
Issued May 8, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30657
- Date
- May 8, 2023
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of the indication for the treatment of invasive candidiasis/candidemia to non-neutropenic pediatric patients at least 1 month of age; Product Monograph update to the master template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ERAXIS | Not yet assigned | — |
Medicinal ingredients
- ANIDULAFUNGIN 100 MG per VIAL